Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Here's Why

Key Points

• Dianthus Therapeutics' stock hit a new 52-week high, reaching $39.22 during trading, and currently has a market cap of $1.26 billion.
• Multiple analysts have upgraded their ratings for the company, with price targets raised significantly, including Robert W. Baird increasing it to $67.00 and Guggenheim raising it to $100.00.
• The company recently reported a quarterly loss of ($0.88) earnings per share, missing analyst estimates, alongside a revenue of $0.19 million compared to expectations of $0.87 million.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $39.22 and last traded at $39.18, with a volume of 87083 shares traded. The stock had previously closed at $37.47.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wedbush increased their price objective on Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Friday, September 12th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, September 8th. Robert W. Baird raised their target price on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an "outperform" rating in a report on Tuesday, September 9th. Guggenheim raised their target price on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, September 9th. Finally, Raymond James Financial restated an "outperform" rating and set a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. Nine investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $61.57.

Dianthus Therapeutics Stock Up 4.5%

The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -12.04 and a beta of 1.46. The business has a 50-day moving average of $23.77 and a two-hundred day moving average of $20.76.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 16.56% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC boosted its holdings in Dianthus Therapeutics by 3.4% during the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock valued at $332,000 after purchasing an additional 602 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after purchasing an additional 618 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Dianthus Therapeutics by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock valued at $1,336,000 after purchasing an additional 748 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company's stock valued at $3,049,000 after acquiring an additional 1,081 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $27,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.